000 01316 a2200337 4500
005 20250517233442.0
264 0 _c20191107
008 201911s 0 0 eng d
022 _a2325-6621
024 7 _a10.1513/AnnalsATS.201806-400PP
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aSchatz, Michael
245 0 0 _aImplications of Changes in U.S. Food and Drug Administration Prescribing Information Regarding the Safety and Use of Asthma Biologics during Pregnancy.
_h[electronic resource]
260 _bAnnals of the American Thoracic Society
_c10 2018
300 _a1131-1136 p.
_bdigital
500 _aPublication Type: Journal Article; Review
650 0 4 _aAnti-Asthmatic Agents
_xpharmacology
650 0 4 _aAsthma
_xdrug therapy
650 0 4 _aBiological Products
_xpharmacology
650 0 4 _aDrug Prescriptions
_xstandards
650 0 4 _aFemale
650 0 4 _aHumans
650 0 4 _aPregnancy
650 0 4 _aPregnancy Complications
_xdrug therapy
650 0 4 _aUnited States
650 0 4 _aUnited States Food and Drug Administration
700 1 _aKrishnan, Jerry A
700 1 _aChambers, Christina
773 0 _tAnnals of the American Thoracic Society
_gvol. 15
_gno. 10
_gp. 1131-1136
856 4 0 _uhttps://doi.org/10.1513/AnnalsATS.201806-400PP
_zAvailable from publisher's website
999 _c28752206
_d28752206